NIH and Santhera Announce Positive Results of Study with SNT-MC17
The US National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) presented results of their recently completed clinical trial with SNT-MC17/idebenone in Friedreich’s Ataxia (FRDA). Data were presented by Dr. Nicholas Di Prospero at the 3rd International Scientific Friedreich’s Ataxia Conference in Bethesda, MD, on November 10 to 12. This six month double-blind, placebo-controlled trial was carried out in collaboration with Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases.
Read More: NIH and Santhera Announce Posi tive Results of Study with SNT-MC17